BACKGROUND:Mansonella perstans infection is common in areas of Africa where Wuchereria bancrofti, a causative agent of lymphatic filariasis, is endemic. M. perstans is refractory to standard antifilarial therapies. The recent discovery of bacterial endosymbionts (e.g., wolbachia) in most filarial species, including M. perstans, provides new therapeutic options for reducing microfilaremia. METHODS: In an open-label, randomized trial, we recruited subjects with M. perstans microfilaremia, with or without concomitant W. bancrofti infection, from four villages in Mali and randomly assigned them to receive doxycycline, at a dose of 200 mg daily for 6 weeks (106 subjects), or no treatment (110). At 6 months, subjects who were coinfected with W. bancrofti underwent a second random assignment, to treatment with a single dose of albendazole (400 mg) and ivermectin (150 microg per kilogram of body weight) or no treatment. Subjects were monitored daily during the first 6-week study period for adverse events. M. perstans and W. bancrofti microfilarial levels were assessed at 6, 12, and 36 months. RESULTS: At 12 months, 67 of 69 subjects who had received treatment with doxycycline only (97%) had no detectable M. perstans microfilariae per 60 microl of blood, as compared with 10 of 63 subjects who had received no treatment (16%) (relative risk, 6.18; 95% confidence interval, 3.63 to 11.89; P<0.001). At 36 months, M. perstans microfilaremia remained suppressed in 48 of 64 subjects who had received treatment with doxycycline only (75%), a finding that was consistent with a macrofilaricidal effect of doxycycline. Vomiting was more frequent in the doxycycline-treated group than in the untreated group (17% vs. 4%). CONCLUSIONS: These results are consistent with previous findings that M. perstans harbors the intracellular endosymbiont, wolbachia, and suggest that doxycycline is an effective therapy for M. perstans infection. (ClinicalTrials.gov number, NCT00340691.) 2009 Massachusetts Medical Society
RCT Entities:
BACKGROUND:Mansonella perstans infection is common in areas of Africa where Wuchereria bancrofti, a causative agent of lymphatic filariasis, is endemic. M. perstans is refractory to standard antifilarial therapies. The recent discovery of bacterial endosymbionts (e.g., wolbachia) in most filarial species, including M. perstans, provides new therapeutic options for reducing microfilaremia. METHODS: In an open-label, randomized trial, we recruited subjects with M. perstans microfilaremia, with or without concomitant W. bancrofti infection, from four villages in Mali and randomly assigned them to receive doxycycline, at a dose of 200 mg daily for 6 weeks (106 subjects), or no treatment (110). At 6 months, subjects who were coinfected with W. bancrofti underwent a second random assignment, to treatment with a single dose of albendazole (400 mg) and ivermectin (150 microg per kilogram of body weight) or no treatment. Subjects were monitored daily during the first 6-week study period for adverse events. M. perstans and W. bancrofti microfilarial levels were assessed at 6, 12, and 36 months. RESULTS: At 12 months, 67 of 69 subjects who had received treatment with doxycycline only (97%) had no detectable M. perstans microfilariae per 60 microl of blood, as compared with 10 of 63 subjects who had received no treatment (16%) (relative risk, 6.18; 95% confidence interval, 3.63 to 11.89; P<0.001). At 36 months, M. perstans microfilaremia remained suppressed in 48 of 64 subjects who had received treatment with doxycycline only (75%), a finding that was consistent with a macrofilaricidal effect of doxycycline. Vomiting was more frequent in the doxycycline-treated group than in the untreated group (17% vs. 4%). CONCLUSIONS: These results are consistent with previous findings that M. perstans harbors the intracellular endosymbiont, wolbachia, and suggest that doxycycline is an effective therapy for M. perstansinfection. (ClinicalTrials.gov number, NCT00340691.) 2009 Massachusetts Medical Society
Authors: Mark J Taylor; Williams H Makunde; Helen F McGarry; Joseph D Turner; Sabine Mand; Achim Hoerauf Journal: Lancet Date: 2005 Jun 18-24 Impact factor: 79.321
Authors: Paul B Keiser; Yaya Coulibaly; Joseph Kubofcik; Abdallah A Diallo; Amy D Klion; Sekou F Traoré; Thomas B Nutman Journal: Mol Biochem Parasitol Date: 2008-05-02 Impact factor: 1.759
Authors: S Chanteau; J P Moulia-Pelat; P Glaziou; N L Nguyen; P Luquiaud; C Plichart; P M Martin; J L Cartel Journal: J Infect Dis Date: 1994-07 Impact factor: 5.226
Authors: Paul B Keiser; Yaya I Coulibaly; Falaye Keita; Diakaridia Traore; Abdallah Diallo; Dapa A Diallo; Roshanak T Semnani; Ogobara K Doumbo; Sekou F Traore; Amy D Klion; Thomas B Nutman Journal: Am J Trop Med Hyg Date: 2003-09 Impact factor: 2.345
Authors: Merepen A Guindo; Joseph P Shott; Renion Saye; Moussa L Diakité; Sintry Sanogo; Moussa B Dembele; Sekouba Keita; Mary C Nagel; Ruth D Ellis; Joan A Aebig; Dapa A Diallo; Ogobara K Doumbo Journal: Am J Trop Med Hyg Date: 2012-04 Impact factor: 2.345
Authors: Fernando Cobo; Ma Teresa Cabezas-Fernández; Joaquín Salas-Coronas; Ma Isabel Cabeza-Barrera; José Vázquez-Villegas; Manuel J Soriano-Pérez Journal: J Immigr Minor Health Date: 2015-02
Authors: Sasisekhar Bennuru; Grace Maldarelli; V Kumaraswami; Amy D Klion; Thomas B Nutman Journal: Am J Trop Med Hyg Date: 2010-10 Impact factor: 2.345
Authors: Nathália F Lima; Cecilia A Veggiani Aybar; María J Dantur Juri; Marcelo U Ferreira Journal: Pathog Glob Health Date: 2016-05 Impact factor: 2.894